UAE Gene Therapy Market By Type (Gene Augmentation, Gene Silencing, Others), By Application (Oncological Diseases, Genetic Diseases, Cardiovascular Diseases, Neuromuscular Diseases, Hematological Diseases, Infectious Diseases, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 51.89 Million
CAGR (2026-2031)	3.84%
Fastest Growing Segment	Gene Augmentation
Largest Market	Dubai
Market Size (2031)	USD 65.05 Million

Market Overview

The UAE Gene Therapy Market will grow from USD 51.89 Million in 2025 to USD 65.05 Million by 2031 at a 3.84% CAGR. Gene therapy involves modifying a patient's genetic material to treat or prevent diseases, holding substantial promise for addressing various genetic disorders, cancers, and chronic conditions. The United Arab Emirates (UAE) market for this advanced medical approach is primarily driven by significant government initiatives aimed at healthcare innovation and the notable prevalence of genetic conditions within the population. For instance, according to the Abu Dhabi Department of Health, the Healthcare Life Science Vision and Strategy in 2023 outlined plans to increase economic activity by $32 billion through enhancing the life sciences sector, including a goal to launch 290 biotech startups and establish 24 new life sciences manufacturing sites in Abu Dhabi.

However, a significant challenge impeding the market's expansion is the substantial cost associated with developing, producing, and administering these highly specialized treatments. The considerable financial burden can limit patient access and pose complexities for insurance coverage and reimbursement frameworks within the UAE healthcare system.

Key Market Drivers

Prevalence of inherited disorders drives demand for gene therapy
The high prevalence of genetic disorders across the UAE population represents a primary driving force for the gene therapy market. Conditions such as thalassemia, sickle cell anemia, and various metabolic disorders are relatively common, necessitating advanced therapeutic solutions. The urgent need to address these inherited diseases encourages investment and development in gene therapy, offering the potential for single-treatment curative outcomes. According to HealthFinder.ae, May 2026, in its article 'UAE Premarital Genetic Testing Requirements in 2026', mandatory genetic testing for Emirati couples before marriage, introduced in January 2025, covers 570 genes associated with more than 840 medical conditions. This widespread screening helps identify individuals who could benefit from early intervention with gene therapies, thereby expanding the potential patient pool and stimulating market growth.

Government investment accelerates the UAE gene therapy landscape
Robust government investment in healthcare innovation is another critical driver shaping the UAE gene therapy landscape. The nation's strategic vision emphasizes developing a knowledge-based economy and establishing itself as a hub for advanced medical research and biotechnology. This commitment translates into substantial funding for research and development, infrastructure upgrades, and support for pioneering medical treatments. For instance, according to a report by the Ministry of Health and Prevention, June 2026, cited by Spectronix Consultancy, investment within the healthcare technology sector saw a staggering 35% year-on-year increase. Such financial backing facilitates the establishment of specialized centers and attracts global expertise. Overall, the UAE's healthcare market reached nearly $22 billion in 2026, according to MedTech World Dubai in 2026, underscoring the broader financial commitment to the health sector which benefits innovative areas like gene therapy.

Download Free Sample Report

Key Market Challenges

High Costs Limit Patient Access and Market Growth
The substantial cost associated with developing, producing, and administering gene therapies directly hampers the growth of the UAE Gene Therapy Market. This significant financial burden creates a primary barrier to patient access, as these treatments often involve considerable expense. Consequently, this complexity extends to insurance coverage and reimbursement frameworks within the UAE healthcare system, making it difficult for many individuals to afford these advanced medical approaches. High treatment costs necessitate robust financial planning and often lead to prolonged negotiation processes between healthcare providers, patients, and insurers.

Rising Healthcare Costs Challenge Adoption of Expensive Therapies
This upward trend in overall medical expenditure exacerbates the challenge for highly specialized and expensive treatments like gene therapy, limiting their widespread adoption and market expansion. According to the Global Medical Trends Survey, medical costs in the UAE were expected to rise by 12% in 2025. This general increase in healthcare costs further strains budgets, impacting the ability of the system to integrate costly, innovative therapies into standard care.

Key Market Trends

Expansion of Precision Medicine and Personalized Therapeutics in the UAE
The growing focus on personalized medicine and precision therapeutics represents a significant trend in the UAE Gene Therapy Market. This approach involves tailoring medical treatments to the individual characteristics of each patient, including their genetic makeup, which aligns perfectly with the core principles of gene therapy. The emphasis on precision allows for more effective and targeted interventions for various genetic disorders, cancers, and chronic conditions. This shift is part of a broader healthcare evolution in the region. According to BioPharma APAC, April 2025, in an article referencing the Abu Dhabi Declaration, the UAE's longevity market, which explicitly includes precision medicine and personalized therapeutics, is estimated to reach $32 billion by 2026. This substantial growth indicates increasing investment and development in highly individualized treatment modalities.

UAE Emerging as a Regional Hub for Advanced Gene Therapy Trials
Another prominent trend is the emergence of the UAE as a regional hub for advanced gene therapy trials and treatments. This development is supported by strategic initiatives aimed at establishing a robust ecosystem for medical innovation and advanced therapies. The country is attracting international collaborations and launching pioneering projects to position itself as a leading destination for specialized medical care and research. For instance, the Abu Dhabi Stem Cell Center, an institution integrating gene therapies, performed over 113 bone marrow transplants in 2025. This demonstrates a tangible increase in the capacity and activity for complex, advanced treatments within the country, solidifying its role as a key center for innovative genetic interventions in the wider region.

Segmental Insights

Gene Augmentation: Fastest-Growing UAE Segment Driven by Therapeutic Promise, Disease Burden, and Regulatory Support
The Gene Augmentation segment is currently the fastest-growing in the UAE Gene Therapy Market. This rapid expansion is primarily driven by its inherent ability to effectively treat inherited genetic diseases through the introduction of functional gene copies, thereby restoring or enhancing gene function. The high prevalence of genetic disorders within the UAE population creates a significant demand for such curative therapeutic approaches. Furthermore, the UAE government's strategic focus on advancing its healthcare sector, coupled with substantial investments in biotechnology and a supportive regulatory framework, including the Human Genome Law, fosters an environment conducive to the adoption and development of innovative gene augmentation therapies.

Regional Insights

Dubai Leads UAE Gene Therapy Market Through Infrastructure, Regulation, and Investment
Dubai leads the UAE Gene Therapy Market due to its established world-class healthcare infrastructure, featuring state-of-the-art medical facilities, advanced hospitals, and specialized clinics equipped for innovative gene therapy treatments and clinical trials. The emirate's commitment to healthcare excellence is supported by a favorable regulatory environment overseen by entities such as the Dubai Health Authority, which fosters both international biotech firm engagement and local innovation. Furthermore, strategic government investments have created a conducive ecosystem that attracts top-tier medical talent and a significant number of international patients seeking advanced therapies. This environment has enabled Dubai to achieve significant milestones, including pioneering gene therapy administrations for complex conditions, solidifying its position within the regional market.

Recent Developments

• In July 2025, Emirates Health Services (EHS) spearheaded groundbreaking initiatives focused on pediatric cell and gene therapies in the UAE. Collaborating with the Children's Hospital of Philadelphia, EHS launched projects aimed at treating rare neurological and genetic disorders in children, including conditions like monogenic autism and epilepsy-linked disorders. Separately, the Department of Health – Abu Dhabi partnered with UCSF and IGIE to establish the world's first genome surgery centers and further collaborated with CNH to advance pediatric cell and gene therapies. These efforts represented a shift towards addressing the root causes of disease and enhancing access to advanced treatments for children across the UAE.
• In March 2025, the Department of Health – Abu Dhabi (DoH) and the Abu Dhabi Stem Cells Center (ADSCC) introduced CASGEVY, a novel CRISPR/Cas9 gene-editing therapy, to the UAE market. This marked a significant advancement in treating sickle cell disease and transfusion-dependent beta-thalassemia, as it represented the first time such an advanced gene therapy was offered in the country. The therapy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, became available with the first patient expected to begin treatment at Yas Clinic Hospital in April 2025. This launch underscored Abu Dhabi's strategic efforts to integrate cutting-edge therapies into its healthcare system.
• In November 2024, the Regenerative Medical Technology Group Inc. (RMTG), also known as Global Stem Cells Group, announced the opening of a new clinic in Dubai. The clinic, situated at the Hyatt Hotel in Jumeirah, aimed to expand the availability of advanced regenerative solutions, including stem cell treatments and exosome applications, within the UAE. This strategic move reinforced Dubai's growing reputation as a hub for medical tourism and advanced healthcare, contributing to the broader market for sophisticated cellular and gene-based therapies. The facility was designed to enhance patient access to innovative regenerative medicine treatments across the region.
• In June 2024, a notable collaboration was established between the Department of Health – Abu Dhabi (DoH) and Opus Genetics, a clinical-stage gene therapy company. This partnership aimed to accelerate the development of innovative gene therapies specifically for patients suffering from rare inherited retinal diseases within the UAE. The Memorandum of Understanding was signed during the BIO 2024 International Convention, highlighting a joint commitment to scientific innovation and addressing unmet medical needs in inherited retinal conditions. This initiative leveraged the UAE's genomic programs with Opus Genetics' expertise, advancing the UAE's gene therapy research landscape.

Key Market Players

• G42 Healthcare
• M42 Health
• PureHealth Holding PJSC
• Gulf Pharmaceutical Industries
• Neopharma LLC
• Globalpharma Co. LLC
• Dubai Biotechnology & Research Park
• Cleveland Clinic Abu Dhabi
• Sheikh Shakhbout Medical City
• National Reference Laboratory

By Type	By Application	By Region
Gene Augmentation Gene Silencing Others	Oncological Diseases Genetic Diseases Cardiovascular Diseases Neuromuscular Diseases Hematological Diseases Infectious Diseases Others	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Gene Therapy Market, By Type:

• Gene Augmentation
• Gene Silencing
• Others

• UAE Gene Therapy Market, By Application:

• Oncological Diseases
• Genetic Diseases
• Cardiovascular Diseases
• Neuromuscular Diseases
• Hematological Diseases
• Infectious Diseases
• Others

• UAE Gene Therapy Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE